Psoriasis Flashcards
Apremilast
Cytokine modulator
Inhibits phosphodiesterase 4, reducing production of pro-inflammatory cytokines, such as TNF‑alpha, interleukin‑17 and ‑23, and increasing anti-inflammatory cytokines such as interleukin‑10.
Bimekizumab
Cytokine modulator
Inhibits the activity of the cytokines interleukin‑17A, ‑17F and ‑17AF, which are involved in inflammatory and immune responses.
Guelkumab
Cytokine modulator
Inhibits the activity of interleukin‑23, a cytokine that is involved in inflammatory and immune responses.
Ixekizumab
Cytokine modulator
Inhibits the activity of interleukin‑17A, a cytokine that is involved in inflammatory (eg keratinocyte hyperproliferation) and immune responses.
Risankizumab
Inhibits the activity of interleukin‑23, a cytokine that is involved in inflammatory and immune responses.
Secukinumab
Cytokine modulator
Inhibits the activity of interleukin‑17A, a cytokine that is involved in inflammatory and immune responses.
Tildrakizumab
Cytokine modulator
Inhibits the activity of interleukin‑23, a cytokine that is involved in inflammatory and immune responses.
Ustekinumab
Cytokine modulator
Inhibits the activity of the cytokines interleukin‑12 and ‑23, which are involved in inflammatory and immune responses.
Calcipotriol/calcipotriene
Vitamin D analogue
Calcipotriol induces differentiation and suppresses proliferation of keratinocytes, reversing the abnormal keratinocyte changes in psoriasis.
Dithranol/anthralin
Exact mechanism is unknown. Restores normal rate of epidermal cell proliferation and keratinisation by reducing the mitotic activity of the hyperplastic epidermis. Therefore, dithranol is particularly good for thick plaque psoriasis.
Methoxsalan
SAS product
The therapeutic effect of UVA-activated psoralens for psoriasis probably involves binding to DNA and inhibition of DNA synthesis, resulting in decreased cell proliferation. In the absence of UV light, psoralens are inert.
Salicylic acid
Keratolytic, weak antifungal and antibacterial actions.
